ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

NSABP Disputed NCI Cost Estimate For P-4 Trial.

May 25, 2007

In Brief: Loberg Resigns From Bristol-Myers Squibb; Bloomfield Heads Cancer Center At Ohio State

February 14, 1997

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

April 16, 1999

Fisher Files Motion In Database Flagging Suit; Documents Examine Role Of Former NCI Director Broder

October 20, 1995

Pfizer Begins Phase III Trial Of Sunitinib In NSCLC

September 28, 2007

NCI Advisory Groups To Be Cut By One-Third

April 22, 1977